BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32833260)

  • 1. Outcomes in N3 Head and Neck Squamous Cell Carcinoma and Role of Upfront Neck Dissection.
    Boros A; Blanchard P; Dade A; Gorphe P; Breuskin I; Even C; Nguyen F; Deutsch E; Bidault F; Janot F; Temam S; Mirghani H; Tao Y
    Laryngoscope; 2021 Mar; 131(3):E846-E850. PubMed ID: 32833260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemotherapy followed by radiotherapy for N3 head and neck squamous cell carcinoma.
    Du C; Blanchard P; Even C; Boros A; Gorphe P; Breuskin I; Baste-Rotllan N; Nguyen F; Ruffier A; Bidault F; Billard C; Janot F; Mirghani H; Temam S; Tao Y
    Head Neck; 2020 Mar; 42(3):426-433. PubMed ID: 31800157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival outcomes for head and neck cancer patients with N3 cervical nodal metastases.
    Virk JS; Ingle M; Podesta CM; Gujral DM; Awad Z
    Clin Otolaryngol; 2020 May; 45(3):342-349. PubMed ID: 31869000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative chemoradiotherapy in patients with head and neck cancer aged 70 or older with positive margins or extranodal extension and the influence of nodal classification.
    Yoshida EJ; Luu M; David JM; Kim S; Mita A; Scher K; Shiao SL; Tighiouart M; Ho AS; Zumsteg ZS
    Head Neck; 2018 Jun; 40(6):1228-1236. PubMed ID: 29417700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of the time interval between surgery and adjuvant radio (chemo) therapy in HPV-negative and advanced head and neck carcinoma of unknown primary (CUP).
    Balk M; Rupp R; Mantsopoulos K; Allner M; Grundtner P; Mueller SK; Traxdorf M; Eckstein M; Speer S; Semrau S; Fietkau R; Iro H; Hecht M; Gostian AO
    BMC Cancer; 2021 Nov; 21(1):1236. PubMed ID: 34794411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-front neck dissection followed by definitive (chemo)-radiotherapy in head and neck squamous cell carcinoma: Rationale, complications, toxicity rates, and oncological outcomes - A systematic review.
    Elicin O; Nisa L; Dal Pra A; Bojaxhiu B; Caversaccio M; Schmücking M; Aebersold DM; Giger R
    Radiother Oncol; 2016 May; 119(2):185-93. PubMed ID: 26996775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
    Karakaya E; Yetmen O; Oksuz DC; Dyker KE; Coyle C; Sen M; Prestwich RJ
    Oral Oncol; 2013 Jan; 49(1):55-9. PubMed ID: 22858313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
    Schüttrumpf L; Marschner S; Scheu K; Hess J; Rietzler S; Walch A; Baumeister P; Kirchner T; Ganswindt U; Zitzelsberger H; Belka C; Maihoefer C
    Radiat Oncol; 2020 Jan; 15(1):7. PubMed ID: 31906998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data.
    Bauml JM; Vinnakota R; Anna Park YH; Bates SE; Fojo T; Aggarwal C; Di Stefano J; Knepley C; Limaye S; Mamtani R; Wisnivesky J; Damjanov N; Langer CJ; Cohen RB; Sigel K
    Cancer; 2019 Feb; 125(3):406-415. PubMed ID: 30341983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional control, progression-free survival and morbidity rates in N3 head and neck cancer patients with low primary tumour burden: A 301-patient study.
    Carsuzaa F; Dufour X; Gorphe P; Righini C; Cosmidis A; Rogé M; De Mones E; Servagi Vernat S; Tonnerre D; Morinière S; Dugas A; Malard O; Pasquier F; Vergez S; Schick U; Gérard M; Salleron J; Thariat J
    Clin Otolaryngol; 2020 Nov; 45(6):877-884. PubMed ID: 32729227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of pathological complete remission after preoperative irradiation in patients with locally advanced head and neck squamous cell carcinoma: re-analysis of a phase 3 clinical study.
    Wang K; Yi J; Huang X; Qu Y; Luo J; Xiao J; Zhang S; Tang Y; Liu W; Xu G; Gao L; Xu Z; Liu S; Wang X
    Radiat Oncol; 2019 Dec; 14(1):225. PubMed ID: 31831042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of bimodality definitive chemoradiation does not differ from that of trimodality upfront neck dissection followed by adjuvant treatment for >6 cm lymph node (N3) head and neck cancer.
    Chen WY; Chen TC; Lai SF; Liang TH; Huang BS; Wang CW
    PLoS One; 2019; 14(12):e0225962. PubMed ID: 31794576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Tumor control and late toxicity.
    Nevens D; Duprez F; Bonte K; Deron P; Huvenne W; Laenen A; De Neve W; Nuyts S
    Radiother Oncol; 2017 Aug; 124(2):220-224. PubMed ID: 28756006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of induction chemotherapy for N3 head and neck squamous cell carcinoma.
    Nishikawa D; Hanai N; Ozawa T; Hirakawa H; Suzuki H; Nakashima T; Hasegawa Y
    Auris Nasus Larynx; 2015 Apr; 42(2):150-5. PubMed ID: 25498333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
    Essers PBM; van der Heijden M; Vossen D; de Roest RH; Leemans CR; Brakenhoff RH; van den Brekel MWM; Bartelink H; Verheij M; Vens C
    Int J Cancer; 2020 Sep; 147(6):1732-1739. PubMed ID: 32167160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgery or Radiotherapy of the Primary Tumor in T1-2 Head and Neck Squamous Cell Carcinoma with Resectable N3 Nodes: A Multicenter GETTEC Study.
    Carsuzaa F; Thariat J; Gorphe P; Righini C; Cosmidis A; Thureau S; Roge M; De Mones E; Servagi-Vernat S; Tonnerre D; Morinière S; Dugas A; Malard O; Pasquier F; Vergez S; Salleron J; Dufour X
    Ann Surg Oncol; 2019 Oct; 26(11):3673-3680. PubMed ID: 31264120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.
    Mohamed A; Twardy B; Zordok MA; Ashraf K; Alkhoder A; Schrapp K; Steuer C; Chen Z; Pakkala S; Pillai R; Trad Wadsworth J; Higgins K; Beitler JJ; Ramalingam SS; Owonikoko TK; Khuri FR; Shin DM; Behera M; Saba NF
    Head Neck; 2019 May; 41(5):1490-1498. PubMed ID: 30835900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
    Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE
    Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
    Tao Y; Aupérin A; Graff P; Lapeyre M; Grégoire V; Maingon P; Geoffrois L; Verrelle P; Calais G; Gery B; Martin L; Alfonsi M; Deprez P; Bardet E; Pignon T; Rives M; Sire C; Bourhis J
    Oral Oncol; 2017 Aug; 71():61-66. PubMed ID: 28688693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy.
    Chandrasekara S; Davis S; Thomson P; Haydon A
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e442-e447. PubMed ID: 29345108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.